Our findings indicated that the lncRNA NBR2 might suppress the progression of colorectal cancer in vitro and in vivo by regulating the polarization of TAM, which could be developed as an important biomarker for the diagnosis and treatment of clinical CRC. This evidence concerns the gene NBR2 and colorectal carcinoma.